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ADAM10-Mediated E-Cadherin Release Is Regulated
by Proinflammatory Cytokines and Modulates
Keratinocyte Cohesion in Eczematous Dermatitis
Thorsten Maretzky1,3,4, Felix Scholz2,3, Bente Ko¨ten2,3, Ehrhardt Proksch2, Paul Saftig1 and Karina Reiss1
Acute eczema is an inflammatory skin disease characterized by the formation of small intraepidermal blisters,
reduction of the adhesion molecule E-cadherin from the keratinocyte surface, and impaired keratinocyte
cohesion. Here, we reveal that the disintegrin and metalloprotease ADAM10 is critically involved in regulating
E-cadherin cell-surface expression in cultured primary human keratinocytes and in diseased human skin.
Proinflammatory cytokines, transforming growth factor-b, and lipopolysaccharide led to increased release of
soluble E-cadherin by activating mitogen-activated protein kinase signaling in cultured keratinocytes. Moreover,
these stimuli decreased the amount of pro-ADAM10 and increased the level of the active protease, leading to
loss of E-cadherin from the cell surface and decreased keratinocyte cohesion. In situ examination and
immunoblot analyses of E-cadherin and ADAM10 expression in lesional skin of eczema revealed that the
reduction of E-cadherin expression in areas of blister formation closely correlated with increased level of
ADAM10 expression and elevated E-cadherin shedding. Our data suggest that ADAM10-mediated E-cadherin
proteolysis leads to the impaired cohesion of keratinocytes observed in eczematous dermatitis and provide
previously unreported insights into the understanding of the molecular mechanisms involved in inflammatory
diseases with loss in epithelial integrity.
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INTRODUCTION
E-cadherin is a prime mediator of epithelial cell-to-cell
interactions (Takeichi, 1991). This type I transmembrane
protein mediates adhesion through Ca2þ -dependent, homo-
typic interactions. Regulating E-cadherin function is a dynamic
process associated not only with physiological changes such
as cellular rearrangements and movements but also with
pathologic processes such as epithelial diseases or cancer.
Proteolytic processing of E-cadherin is an important
mechanism for regulating E-cadherin cell-surface expression
and rapid changes in epithelial cell function. This metallo-
protease-mediated process leads to the generation of a
C-terminal 38 kDa membrane-bound fragment and an
80 kDa soluble E-cadherin ectodomain (Marambaud et al.,
2002). Elevated levels of soluble E-cadherin have been
detected in the serum of patients with tumors such as
metastatic malignant melanoma, bladder cancer, or color-
ectal cancer (Griffiths et al., 1996; Shirahama et al., 1996;
Velikova et al., 1998). For gastric carcinoma, the level of
soluble E-cadherin appears to be a valid prognostic marker
(Chan et al., 2001, 2003, 2005). Also, in several inflam-
matory skin diseases, such as Darier’s disease, psoriasis
vulgaris, pemphigus vulgaris, and atopic dermatitis, increased
serum levels of soluble E-cadherin have been described
(Matsuyoshi et al., 1995; Furukawa et al., 1997).
Eczema (dermatitis) is an inflammatory skin disease.
Atopic dermatitis affects 2–16% of children worldwide with
increasing prevalence (Williams et al., 2004). The disease is
clinically characterized by scaling, redness, and pruritus. In
acute eczema, small intraepidermal blisters may occur.
Blister formation is histologically termed spongiosis and is
characterized by a widening of the intercellular spaces
between epidermal keratinocytes because of reduced kera-
tinocyte cohesion. A disturbed skin barrier function due to
disturbed epidermal differentiation in eczema may result in
the invasion of harmful environmental substances into the
skin leading to a toxic or allergic response that aggravates
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dermatitis (Ogawa and Yoshiike, 1993; Proksch et al., 2003;
Jensen et al., 2004; Hudson, 2006). The molecular mecha-
nisms of the pathogenetic events in dermatitis are far from
being understood (Engelhart et al., 2005).
We recently demonstrated that ADAM10, a member of
the a disintegrin and metalloprotease family, is responsible
for the release of E-cadherin in transfected murine fibroblasts
and in the spontaneously immortalized human keratinocyte
cell line HaCaT (Maretzky et al., 2005a). ADAMs have been
implicated in a wide range of biological processes such as
the control of membrane fusion, cell fate determination, and
inflammation (Seals and Courtneidge, 2003). ADAM10 plays
a critical role during neurogenesis, in Notch signaling, and in
the regulation of neuronal cell adhesion (Rooke et al., 1996;
Pan and Rubin, 1997; Hartmann et al., 2002; Reiss et al.,
2005). The protease shows a very prominent expression in all
epithelial tissues, especially in the epidermis and in the
epithelial tissues of kidney, liver, and heart during develop-
ment (Hall and Erickson, 2003). This expression pattern
suggests that ADAM10 has a crucial role in epithelial tissue
homeostasis. We therefore analyzed the role of ADAM10 for
E-cadherin processing in cultured primary human keratino-
cytes and in human epidermis in disease.
We demonstrate that ADAM10 is the major protease
responsible for E-cadherin release in primary human kerati-
nocytes. This shedding can be activated by different soluble
factors associated with epidermal dysfunction such as pro-
inflammatory cytokines, transforming growth factor-b
(TGF-b), and lipopolysaccharide (LPS). The elevated level
of ADAM10 correlated with an increased shedding of
E-cadherin in eczematous human epidermis as determined by
immunoblot analysis and in situ examination. Our findings
indicate that the activation of ADAM10-mediated E-cadherin
proteolysis leads to the loss of keratinocyte adhesion. These
observations suggest that ADAM10/E-cadherin interaction
might represent a common regulatory mechanism in inflam-
matory epidermal diseases, which are characterized by loss
of E-cadherin expression and loss in epithelial integrity.
RESULTS
ADAM10 mediates constitutive E-cadherin proteolysis in
primary human keratinocytes
Increased levels of soluble E-cadherin have been detected
in patients with several inflammatory skin diseases such as
psoriasis vulgaris, pemphigus vulgaris, and atopic dermatitis.
To determine whether ADAM10 is involved in E-cadherin
proteolysis in human skin, we performed inhibitor studies in
primary human keratinocytes with two hydroxamate-based
compounds that differ in their capacity to block the activities
of ADAM10 and its close homologue ADAM17 (Hundhausen
et al., 2003; Ludwig et al., 2005). The inhibitor GW280264X
has been shown to preferentially block ADAM17 and, to
a slightly lesser extent, ADAM10, while the compound
GI254023X blocked ADAM10 activity. Western blot analyses
of inhibitor-treated primary keratinocytes revealed that the
generation of the membrane-bound 38 kDa C-terminal
fragment (CTF) of E-cadherin was only slightly inhibited
by treatment with GW280264X (Figure 1a). In contrast,
E-cadherin shedding was significantly reduced after treatment
with the preferential ADAM10 inhibitor GI254023X. This
effect was comparable with the effect of the broad-spectrum
metalloprotease inhibitor marimastat and correlated with the
decreased release of the N-terminal E-cadherin fragment in
the supernatant (Figure 1a, lower panel). These findings
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Figure 1. Constitutive ADAM10-mediated E-cadherin shedding in primary
keratinocytes. (a) Cells were treated with the ADAM10 inhibitor
GI254023X (GI), the ADAM17/ADAM10 inhibitor GW280264X (GW), the
broad-spectrum metalloprotease inhibitor marimastat (Ma), or DMSO as
a control. Cell pellets were subjected to immunoblot analyses using a
C-terminal E-cadherin antibody (upper panel), while cell supernatants were
analyzed for NTFs (lower panel). E-cadherin CTF generation was calculated
by densitometric analysis (right panel). Results are expressed as mean±SEM
(n¼3). CTF formation was significantly decreased when cells were treated
with GI or Ma as compared to vehicle-treated cells (*Po0.05).
(b) Overexpression of ADAM10 increased E-cadherin proteolysis. After
western blotting using anti-ADAM10 antibodies, the blot was reprobed with
anti-E-cadherin antibodies. p: precursor of ADAM10; m: mature form of
ADAM10. For densitometric analysis, total ADAM10 and E-cadherin CTF
generation was quantified and compared with the mock-treated cells (100%)
(right panel). ADAM10 overexpression significantly increased E-cadherin CTF
generation (1Po0.05). (c) Cell pellets and supernatants of mock-transfected
or ADAM10 siRNA-transfected cells were harvested directly (0 hour, 100%)
or 48 and 72hours after transfection and analyzed for ADAM10 expression
by real-time PCR. Cell supernatants were analyzed by ELISA for soluble
E-cadherin. E-cadherin proteolysis was additionally controlled by
immunoblot (inset) after 48 hours (2) and 72 hours (3) and compared to
mock-transfected cells (72 hours) (1). E-Cad/FL, full-length E-cadherin.
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suggest that most of the metalloprotease-dependent
E-cadherin processing in primary human keratinocytes can be
attributed to ADAM10. To examine the role of ADAM10 in
more detail, we analyzed E-cadherin processing by gain- and
loss-of-function experiments in primary human keratinocytes.
Overexpression of ADAM10 correlated with significantly
increased E-cadherin CTF generation and decreased level of
full-length E-cadherin (Figure 1b). Vice versa, transfection of
primary keratinocytes with ADAM10 small interfering RNA
(siRNA) led to 80% reduction of ADAM10 mRNA level and
reduced the release of soluble E-cadherin to approximately
40% as determined by ELISA (Figure 1c). The effect on
E-cadherin CTF generation was also confirmed by immunoblot
analysis (Figure 1c, insert). These data confirm the critical role
of ADAM10 as the major E-cadherin sheddase.
Proinflammatory cytokines stimulate the release of soluble
E-cadherin in epithelial cells by activating mitogen-activated
protein kinase signaling
Ectodomain shedding occurs constitutively in unstimulated
cells and in response to a variety of stimuli such as growth
factors or protein kinase C activation (Seals and Courtneidge,
2003). A large number of cytokines, growth factors, and
chemokines contribute to the pathogenesis of inflammatory
epithelial skin diseases such as eczema or psoriasis
(Raychaudhuri et al., 1999; Engelhart et al., 2005). We
examined whether these factors might also regulate ADAM10-
mediated E-cadherin proteolysis. Incubation of primary kerati-
nocytes with the proinflammatory cytokines IL-1b or tumor
necrosis factor-a (TNF-a) and IFN-g significantly increased
E-cadherin CTF generation (Figure 2a). TGF-b signaling
regulates inflammation and proliferation and is known to affect
nearly every aspect of wound repair (Crowe et al., 2000).
Interestingly, TGF-b, but also LPS, a potent activator of inflam-
matory responses (Raetz et al., 1991), was able to stimulate
E-cadherin proteolysis (Figure 2a).
It is well known that cytokines trigger activation of many
cellular signaling pathways. IL-1b-induced signaling involves
activation of the mitogen-activated protein kinase (MAPK)
pathways and activation of the transcription factor NF-kB,
a pathway commonly shared by TNF-a and LPS. Also, TGF-b
triggers MAPK signaling pathways. To analyze whether the
activation of MAPK signaling was required for the observed
increase of E-cadherin shedding, primary human keratino-
cytes were stimulated in the presence of the MEK (MAPK/
extracellular signal-regulated kinase kinase) inhibitor U0126.
The significantly induced release of soluble E-cadherin
(Figure 2b) and E-cadherin CTF generation (data not shown)
was abrogated in the presence of the MAPK inhibitor. These
data suggest that the activation of MAPK signaling represents
an important mechanism to regulate E-cadherin proteolysis
and E-cadherin-associated keratinocyte functions.
ADAM10 mediates stimulated E-cadherin shedding and
modulates keratinocyte cohesion
To determine whether ADAM10 was responsible for the indu-
ced shedding of E-cadherin in primary keratinocytes, cells
were stimulated in the absence or presence of the ADAM10
inhibitor GI254023X. E-cadherin CTF generation, which was
induced by all applied stimuli, was abrogated in the presence
of the ADAM10 inhibitor (Figure 3). These findings indicate
that different inflammatory responses are able to activate
ADAM10-mediated proteolysis of E-cadherin in keratino-
cytes.
To analyze whether the stimulation of ADAM10-mediated
shedding would affect the subcellular localization of E-cadherin
and keratinocyte cohesion, we analyzed E-cadherin expression
by immunocytochemistry (Figure 4). E-cadherin immunostain-
ing was very prominent at cell–cell junctions of mock-treated
cells. IL-1b treatment led to almost complete cell dissociation.
The keratinocytes lost their cell–cell contacts and exhibited a
slightly rounded appearance. Even though the effect of TGF-b
was not as strong as the effect of IL-1b, stimulation resulted in a
loss of E-cadherin from the cell surface and only a few cells
remained tightly clustered. TNF-a/IFN-g stimulation and LPS
treatment affected cell adhesion only slightly, leading to some
small gaps in the keratinocyte monolayer. However, E-cadherin
was retained at the cell surface and the morphological integrity
was unaffected when the cells were treated with the agents
mentioned before in the presence of the ADAM10 inhibitor
GI254023X (Figure 4). These findings strongly suggest that the
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Figure 2. Activation of E-cadherin shedding in primary keratinocytes.
(a) Cells were stimulated overnight with TGF-b (10 ngml1), IL-1b
(10 ngml1), LPS (1 mgml1), INF-g and TNF-a (10 ngml1), or vehicle control
(DMSO) and analyzed for E-cadherin proteolysis by immunoblot. Right panel:
densitometric analysis of two independent experiments. Compared to the
vehicle control, all stimuli significantly increased E-cadherin proteolysis
(*Po0.05). (b) Cells were stimulated overnight with vehicle control,
TGF-b (10 ngml1), IL-1b (10 ngml1), LPS (1 mgml1), or with INF-g and
TNF-a (10 ngml1) for 1 hour in the presence or the absence of the MAPK
inhibitor U0126 (10mM). Release of soluble E-cadherin was determined
by ELISA. Compared to the vehicle control, all stimuli significantly
increased the release of soluble E-cadherin (*Po0.05). U1026 significantly
decreased CTF generation, compared to the respective stimulated cells
(o,þ ,#,y,NPo0.05). E-Cad/FL, full-length E-cadherin.
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applied stimuli lead to decreased epithelial cell–cell adhesion
by an activation of ADAM10-mediated E-cadherin proteolysis.
Stimulation of E-cadherin shedding in keratinocytes is caused by
increased generation of active ADAM10
Our findings indicated the generation of increased amounts
of active ADAM10 due to either transcriptional changes or
differences in the post-translational modification process. It
has been reported that proinflammatory cytokines and growth
factors can modulate the activity of ADAM17, the close
homologue of ADAM10, by affecting the transcriptional
expression of this protein (Bzowska et al., 2004). To analyze
whether the increase in E-cadherin shedding after stimulation
in keratinocytes could also be attributed to increased
ADAM10 mRNA expression, we quantified the level of
ADAM10 transcripts by real-time PCR. After stimulation with
IFN-g/TNF-a or with LPS, an approximately 1.6-fold increase
in ADAM10 mRNA was observed (Figure 5a). The other
applied stimuli showed a very small or even a slightly
negative effect on ADAM10 mRNA levels. These findings
indicate that an elevated ADAM10 activity was more likely
due to post-translational modifications.
ADAMs are synthesized in the rough endoplasmic
reticulum and mature in the late Golgi compartment. This
maturation involves the removal of the prodomain, which
keeps the metalloprotease site inactive. ADAM10 exists as an
B97 kDa inactive proform that is converted to the B68 kDa
active mature form by cleavage at a consensus proprotein
convertase cleavage motif (Anders et al., 2001).
Immunoblot analysis of primary keratinocytes showed
that under unstimulated conditions the amount of
ADAM10 proform was elevated compared to the amount of
mature ADAM10 protein (Figure 5b, control). In contrast,
after stimulation with proinflammatory cytokines, TGF-b, or
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Figure 3. Involvement of ADAM10 in stimulated E-cadherin processing.
Cells were stimulated with IL-1b (10 ngml1), INF-g and TNF-a (10 ngml1),
LPS (1 mgml1), TGF-b (10 ngml1), or vehicle control (DMSO) in the
presence or absence of the ADAM10 inhibitor GI254023X (GI) overnight.
Cell pellets were analyzed for E-cadherin processing by immunoblot analysis
using C-terminal antibodies. Compared to the vehicle control, all stimuli
significantly increased E-cadherin CTF generation (*Po0.05). GI significantly
decreased E-cadherin proteolysis, compared to the respective stimulated
cells (o,þ ,#,y,NPo0.05). E-Cad/FL, full-length E-cadherin.
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Figure 4. Disruption of E-cadherin-dependent adhesion in primary
keratinocytes. Cells were stimulated in the presence or absence of the
ADAM10 inhibitor GI254023X (GI) (5 mM) for 18 hours with IL-1b
(10 ngml1), TNF-a and IFN-g (10 ngml1), TGF-b (10 ngml1), or LPS
(1 mgml1). Afterwards cells were fixed and immunostained for E-cadherin
(red) C-terminal antibodies. Nuclei were counterstained with DAPI. All
applied stimuli lead to loss of E-cadherin cell-surface expression and
reduced cell–cell contacts. This effect was abrogated in the presence of the
ADAM10 inhibitor. Bar¼10 mm. DAPI, 40,6-diamidino-2-phenylindole.
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LPS, pro-ADAM10 was nearly undetectable, whereas the
amount of the mature form increased significantly (Figure 5b).
However, the total amount of ADAM10 was nearly unaffec-
ted by the different stimuli as determined by densitometric
quantification of three independent experiments (Figure 5b,
left panel). These data show that the proinflammatory
cytokines TNF-a, IFN-g, and IL-1b, as well as TGF-b and
LPS, are able to increase ADAM10 activity.
Increased ADAM10 activity in eczematous dermatitis correlates
with elevated E-cadherin proteolysis and blister formation
Eczematous dermatitis is an acute or chronic, often relapsing,
inflammatory skin disease. Acute eczema clinically exhibits
multiple small intraepidermal blisters that are histologically
characterized by spongiosis. Keratinocytes within eczema-
tous lesions exhibit changes in the expression of proinflam-
matory cytokines and chemokines and a loss of E-cadherin
expression (Trautmann et al., 2001; Engelhart et al., 2005).
To examine whether the observed regulation of E-cadherin
shedding by ADAM10 might also be important for the
molecular pathology of this skin disease, we analyzed
the expression of ADAM10 and E-cadherin by immuno-
histochemistry and immunoblot analysis in healthy skin and
in eczematous lesions (Figure 6). In normal skin, E-cadherin
immunoreactivity was detected within all layers of the
epidermis showing a reduced staining in the lower epidermis.
ADAM10 staining was faintly seen in the entire epidermis,
but mainly in the basal cell layers (Figure 6a). In eczema
(Figure 6b–e), the spongiotic vesicle (Figure 6c and d, black
area in the epidermis) is devoid of ADAM10 and E-cadherin
immunoreactivity. The immunofluorescence staining of
specimens from three different patients suffering from
eczema showed that ADAM10 is concentrated in the areas
close to the spongiotic vesicle where E-cadherin expression is
reduced (Figure 6b–d). In these regions, ADAM10 showed a
close localization to the plasma membrane (Figure 6e,
arrowheads).
Taken together, these findings suggest that eczematous
dermatitis is accompanied by increased ADAM10 activity
that leads to the observed loss in E-cadherin expression. This
assumption was further supported by immunoblot analysis of
ADAM10 and E-cadherin protein expression in healthy and in
eczematous skin extracts. As shown in Figure 6f, we observed
a strongly increased expression of ADAM10 (Figure 6f, upper
panel) that correlated with increased E-cadherin proteolysis
(Figure 6f, middle panels) in eczematous skin. These data
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Figure 5. ADAM10 expression in primary keratinocytes. (a) Quantitative real-time PCR analysis of ADAM10 expression in primary human keratinocytes.
Cells were stimulated overnight with IL-1b (10 ngml1), INF-g and TNF-a (10 ngml1), LPS (1 mgml1), TGF-b (10 ngml1), or vehicle control (DMSO).
The mRNA expression level of ADAM10 was determined by real-time PCR and expressed in relation to that of GAPDH. Results were obtained from two
independent experiments and expressed as mean±SEM. (b) Stimulation with TGF-b, IL-1b, LPS, INFg and TNF-a, or vehicle control (DMSO) only slightly
affected the total amount of ADAM10 (proform and mature form; left densitometric analyses). In contrast, the level of inactive pro-ADAM10 decreased
significantly (1),whereas the amount of mature protein significantly increased (right densitometric analyses (*)).
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indicate that ADAM10-mediated E-cadherin proteolysis leads
to the impaired cohesion of keratinocytes observed in
eczematous dermatitis.
DISCUSSION
Cell-surface-expressed E-cadherin represents the main
cell adhesion molecule in epithelial tissues. Changes in
E-cadherin expression have been linked to a variety of
malignancies (Hirohashi, 1998; Trautmann et al., 2001).
Downregulation of E-cadherin occurs in many types of
carcinoma and correlates with the transition to metastasis
(Otto et al., 1993; Yonemura et al., 1995; Ryniers et al.,
2002; Chen et al., 2003). Increased serum levels of soluble
E-cadherin have been detected in carcinoma patients and
patients with epithelial diseases, which are characterized by
impaired keratinocyte adhesion such as eczematous derma-
titis or psoriasis (Matsuyoshi et al., 1995; Griffiths et al., 1996;
Shirahama et al., 1996; Furukawa et al., 1997; Velikova
et al., 1998; Chan et al., 2003, 2005; Engelhart et al., 2005).
In this paper, we demonstrate that the metalloprotease
ADAM10 is critically involved in the release of E-cadherin
from the surface of primary human keratinocytes. Moreover,
our data show that the activity of ADAM10 is tightly regulated
by a variety of different activation mechanisms leading
to increased E-cadherin shedding and thereby possibly
contributing to the loss of keratinocyte adhesion in vivo.
Several members of the ADAMs, such as ADAM17,
ADAM9, or ADAM10, may play a role in the epidermis even
though their physiological roles in this tissue remain unclear
(Izumi et al., 1998; Peschon et al., 1998; Hall and Erickson,
2003). Our experiments using inhibitors and overexpression
analyses as well as RNAi (RNA interference)-mediated
downregulation of ADAM10 in primary keratinocytes clearly
underline the critical role of ADAM10 in the constitutive
cleavage of E-cadherin.
ADAM-mediated constitutive shedding of transmembrane
proteins can be strongly enhanced by external stimuli, such
as phorbol esters, ionophores, and growth factors (Fan et al.,
2003). Although the mechanism of ADAM activation has
been extensively investigated, it is still poorly understood.
The important function of inflammatory mediators in the
pathogenesis and pathophysiology of skin diseases is widely
accepted, but little information is available regarding the
roles of cytokines in shedding events. Therefore, we analyzed
different cytokines and growth factors associated with
epithelial diseases for their influence on ADAM10-mediated
E-cadherin shedding. The proinflammatory cytokines IL-1b,
TNF-a, and IFN-g, which are involved in the pathogenesis of
a variety of inflammatory diseases in several organs including
the skin (Junghans et al., 1998), were able to activate
ADAM10-mediated proteolysis of E-cadherin. TGF-b has
been shown to be overexpressed in keratinocytes in certain
inflammatory skin diseases and to regulate a wide variety of
genes in keratinocytes. Our results indicate that TGF-b is able
to activate ADAM10-mediated cleavage of E-cadherin by
stimulating MAPK signaling. LPS, which is a potent activator
of inflammatory responses involved in allergic diseases and a
possible modulator of atopic eczema (Ormstad et al., 2003),
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Figure 6. ADAM10 and E-cadherin expression in healthy skin and
eczematous dermatitis. Skin sections (a) of healthy skin and (b–d) of
three patients suffering from eczematous dermatitis were stained using
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could also induce E-cadherin proteolysis. Here, it is likely
that LPS binds to Toll-like receptors, which are expressed on
epithelial cells (Pivarcsi et al., 2003), and activates intra-
cellular epithelial signaling, thereby stimulating ADAM10-
mediated proteolysis. Overall, these findings indicate that
there are several distinct and so far unknown activation
mechanisms of ADAM10 activity, which can be of crucial
importance in inflammatory diseases.
Even though all applied stimuli increased ADAM10-
dependent E-cadherin proteolysis, the degree of cell disso-
ciation differed. IL-1b showed the strongest effect, but TGF
treatment also decreased cell adhesion, whereas TNF-a/IFN-g
stimulation affected cell adhesion only slightly. These
differences might be due to the different signaling pathways
and additional downstream effects, which might contribute to
the loss of cell–cell contacts.
Interestingly, it was demonstrated that the proinflamma-
tory cytokines IL-1b and TNF-a upregulated ADAM17-
mediated ectodomain release of the vascular cell adhesion
molecule 1 from murine endothelial cells, and this was
dependent on p38 and MAPK (Singh et al., 2005). In addition,
the shedding of the ADAM17 substrate TGF-a is also induced
through activation of the extracellular signal-regulated kinase
MAPK signaling cascade (Fan and Derynck, 1999). However,
little is known about the signaling mechanisms activating
ADAM10-mediated substrate cleavage. Therefore, our data
demonstrating that E-cadherin shedding is dependent on
MAPK signaling and on ADAM10 activation provide pre-
viously unknown insights into the molecular mechanisms
involved in regulating cell-surface expression and function of
E-cadherin.
Although all stimuli led to an increased ADAM10-
dependent E-cadherin proteolysis, only IFN-g/TNF-a and
LPS treatment were able to slightly increase the level
of ADAM10 mRNA expression in our cell culture system.
Besides differences in transcriptional control, post-transla-
tional modifications are important regulatory events modu-
lating ADAM activity (Huovila et al., 2005). Our findings
indicate that proinflammatory cytokines, TGF-b, and LPS
lead to elevated ADAM10-mediated E-cadherin shedding
by increasing the level of active ADAM10.
In the course of several epithelial diseases such as ecze-
matous dermatitis, the generation of a wide variety of
soluble factors is dysregulated. Eczema comprises a group
of pruritic chronic inflammatory skin diseases characterized
by an impaired cohesion of keratinocytes most pronounced
in the acute form. Impaired keratinocyte cohesion leads to
the widening of intercellular spaces in the epidermis and
to blister formation (Engelhart et al., 2005). Keratinocytes
within eczematous lesions exhibit changes in the expression
of proinflammatory cytokines, chemokines, and cell-surface
molecules. However, the pathophysiological basis of this
disease is far from being elucidated.
Recently, it has been proposed that T-cell-mediated
keratinocyte apoptosis resulting in spongiosis may play a
role in the formation of eczematous dermatitis (Trautmann
et al., 2001). The authors stated that the induction of
keratinocyte apoptosis is accompanied by a rapid cleavage
of E-cadherin and loss of coimmunoprecipitated b-catenin.
In situ examination of E-cadherin expression and cellular
distribution in acute eczematous dermatitis revealed a
reduction in keratinocyte membrane E-cadherin in areas
of spongiosis. Although a sparse infiltrate of T lymphocytes
is always present in the spongiotic areas of eczema, it is
unknown whether the infiltrating T lymphocytes induce the
epidermal changes of eczema or whether T-lymphocyte
infiltration follows epidermal changes (Ogawa and Yoshiike,
1993; Bos et al., 1994; Proksch et al., 2003; Cookson, 2004;
Jensen et al., 2004).
Loss of E-cadherin in keratinocytes leads to a loss of
adherens junctions and altered epidermal differentiation
(Hines et al., 1999; Tinkle et al., 2004). It has been demons-
trated that impaired differentiation contributes to the defec-
tive barrier function found in atopic dermatitis (Proksch et al.,
2006). Therefore, increased activation of ADAM10 and thus
increased E-cadherin proteolysis might influence keratinocyte
differentiation in eczematous skin. On the other hand,
changes in differentiation might also affect ADAM10 activity
and thus E-cadherin shedding. Further studies are required to
find the relation between ADAM activity and keratinocyte
differentiation.
Independent of the sequence of events, our experiments
demonstrate that not only released proinflammatory cyto-
kines, but also growth factors lead to increased ADAM10-
mediated E-cadherin processing in keratinocytes. This finding
was confirmed by our immunohistochemical analysis de-
monstrating enhanced expression of ADAM10 in spongiotic
areas of acute eczema where E-cadherin expression was
reduced. Importantly, immunoblot analysis of eczematous
skin further underlined that the increased ADAM10 expres-
sion correlates with elevated E-cadherin proteolysis in vivo.
Even though it is tempting to speculate that increased
maturation or decreased degradation of ADAM10 contributes
to this phenomenon, excess transcriptional expression of the
protease might conceal this effect. Moreover, our immuno-
histochemical analyses indicate that a shift in ADAM10
localization might represent an additional regulatory mecha-
nism in eczematous skin.
Impaired intercellular adhesion of keratinocytes and
reduced E-cadherin expression have also been observed
in other epidermal disorders such as Hailey–Hailey’s disease,
Darier’s disease, Psoriasis, and pemphigus vulgaris (Burge
and Schomberg, 1992; Furukawa et al., 1994; Chung et al.,
2005). As our presented data highlight the pivotal role
of ADAM10 as E-cadherin sheddase, dysregulation of this
protease is likely to contribute to the pathology of eczema
and may be involved in other inflammatory epithelial
diseases. Moreover, inhibition of ADAM10 may be a
promising target for therapeutic intervention.
MATERIALS AND METHODS
Antibodies and reagents
The mAb against the cytoplasmic domain of E-cadherin (C36) was
purchased from BD Bioscience (San Jose, CA), and the E-cadherin
ectodomain antibody H-108 was obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). For immunoblot analyses, ADAM10
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was detected using a polyclonal antiserum B42.1 described previously
(Hartmann et al., 2002), and for immunostaining a rabbit anti-
ADAM10 polyclonal antibody (Chemicon, Hampshire, UK) was used.
Reagents were obtained as follows: U0126 from Cell Signaling
Technology (Danvers, MA); LPS (HL145), Phorbol-12 myristate
13-acetate (PMA) from Sigma (Taufkirchen, Germany). Hydroxamate-
based inhibitors GW280264X and GI254023X were described else-
where (Hundhausen et al., 2003). Complete EDTA-free protease
inhibitor mixture was obtained from Roche Molecular Biochemicals
(Mannheim, Germany). Marimastat was obtained from British Biotech
(Oxford, UK). Human TNF-a, IFN-g, and IL-1b were purchased from
R&D Systems (Minneapolis, MN), and human TGF-b was obtained
from PeproTech (Rock Hill, NJ).
Human skin samples
Six patients with acute eczema (atopic and contact dermatitis) were
included in this study. Patients were diagnosed by clinical signs and
skin histology. They were not receiving any systemic or potent local
therapy for at least 2 weeks before biopsy. Skin biopsies were taken
from lesional skin. Control biopsies were taken from unaffected skin
of the same patient. All patients had signed an informed consent
before the diagnostic biopsy. This was approved by the ethics
committee of the Medical Faculty of the University Kiel and
conducted according to the Declaration of Helsinki Principles.
Cell culture and transfection
Foreskin-derived primary human keratinocytes were isolated from
neonatal foreskins as described in the literature (Wiedow et al.,
1998) and cultured in EpiLife medium (Cascade Biologics, Portland,
OR) containing EpiLife defined growth supplement, 0.06mM CaCl2,
100Uml1 penicillin, 100 mgml1 streptomycin (both from Gibco,
Grand Island, NY). Cells were used after the second passage. For
stimulation/inhibition experiments, cells were seeded in six-well
tissue culture plates (Sarstedt, Nu¨mbrecht, Germany) in EpiLife
medium containing 1mM CaCl2. Cells were used at a confluence of
80–90%. The medium was changed every second day.
The cloning of mADAM10 in pcDNA3.1 (Invitrogen, Karlsruhe,
Germany) was reported previously (Maretzky et al., 2005b). Cells
were transfected with FuGENE 6 (Roche Molecular Biochemicals)
according to the manufacturer’s instructions.
Keratinocyte stimulation and inhibition experiments
For analysis of constitutive E-cadherin shedding, cells were washed
with phosphate-buffered saline (PBS) and incubated in DMEM with
GI254023X (5 mM), GW280264X (5mM), marimastat (5mM), or DMSO
(Roth, Karlsruhe, Germany) as control for 6 hours. For stimulation
experiments, fetal calf serum-free medium containing metallopro-
tease inhibitors or DMSO was added. After 1 hour preincubation, the
cells were treated with TNF-a/IFN-g (10 ngml1), IL-1b (10 ngml1),
TGF-b (10 ngml1), or LPS (1mgml1) for 18 hours.
Western blotting
Cells were washed once with PBS and lysed in lysis buffer (5mM Tris-
HCl (pH 7.5), 1mM EGTA, 250mM saccharose, 1% Triton X-100)
supplemented with complete inhibitor. The same amounts of protein
were loaded on 10% SDS-PAGEs. Supernatants were analyzed
after acetone precipitation. The samples were electrotransferred
onto polyvinylidene difluoride membranes (Hybond-P; Amersham,
Freiburg, Germany) and blocked overnight with 5% skim milk in
Tris-buffered saline (TBS). After incubation with the indicated
antibody in blocking buffer, the membranes were washed three
times in TBST (TBS containing 0.1% Tween). Primary antibodies
were detected using affinity-purified peroxidase (POD)-conjugated
secondary antibodies for 1 hour at room temperature. Detection was
carried out using the ECL detection system (Amersham). Signals were
recorded by a luminescent image analyzer (image reader LAS1000;
Fujifilm, Tokyo, Japan). For reprobing blots, polyvinylidene
difluoride membranes were incubated in stripping buffer (100mM
2-mercaptoethanol, 2% SDS, 62.5mM Tris-HCl (pH 6.7)) for 1 hour
at 60 1C with occasional shaking. After three washes in large
volumes of TBST, the membranes were blocked in blocking buffer
for 1 hour at room temperature, and immunodetection was repeated.
Quantification of E-cadherin proteolysis
Immunoblots were analyzed with image analyzer software
(Gel-ProAnalyser; Media Cybernetics, Silver Spring, MD). The
generation of C-terminal cleavage products (CTFs) was calculated
as a percentage of total E-cadherin (full-length E-cadherin plus
CTF) by densitometric analysis of three independent experiments or
as otherwise indicated.
siRNA
For downregulation of endogenous ADAM10 expression in human
keratinocytes, the following duplexed RNA oligonucleotides (Stealth
RNAi) were used: 50-AACAGUAGUCAUCAUGAUUCUGCUC-30.
As negative control, unspecific stealth RNA duplexes (Invitrogen)
with low GC content were used. For transfection, human primary
keratinocytes were grown to 60% confluence in six-well plates or in
12-well plates. The siRNA constructs were preincubated with
Lipofectamine 2000 for 20minutes at room temperature and then
applied to the cells at final concentrations of 20 pM in EpiLife
medium without antibiotics. After 6 hours of incubation, the medium
was replaced and the cells were further incubated for 48 or 72 hours.
Cell pellets and supernatants of mock-transfected or ADAM10
siRNA-transfected cells were harvested directly (0 hour, 100%) or 48
and 72 hours after transfection and analyzed for ADAM10 expres-
sion by real-time PCR. Conditioned media were harvested and
analyzed for the presence of processed E-cadherin by ELISA and
immunoblot.
Immunohistology
For immunohistochemical analyses, skin samples from three patients
were taken by 4-mm punch biopsy. The tissue specimens were fixed
in 8% formalin and embedded in paraffin. Unspecific antibody
binding was blocked with 0.1% BSA (PAA Laboratories, Linz,
Austria) and 0.2% glycine in TBS. For blocking of unspecific binding
of antibodies to Fc-receptors, 2 ngml1 sheep IgG Fc-fragments
(Dianova, Hamburg, Germany) was added for 1 hour at room
temperature. Human ADAM10 was detected with a rabbit anti-
ADAM10 antibody (5 mgml1, Chemicon, Temecula, CA) and
E-cadherin was detected using mouse anti-E-cadherin antibodies
(1.25mgml1; BD Bioscience). Sections were incubated overnight at
4 1C. As secondary reagents, Cy2-coupled goat anti-rabbit-IgG and
Cy3-coupled goat anti-mouse-IgG (Dianova) were applied according
to the manufacturer’s recommendations. Nuclei were counterstained
with bisbenzimide in most cases (Hoechst 33258), and sections were
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analyzed by confocal laser scanning microscopy (LSM 510 UV;
Zeiss, Jena, Germany). The specificity of the immunohistochemical
procedures was assessed by means of the negative controls
performed: (a) omitting the primary antibody; (b) using rabbit IgG
for the ADAM10 antibody as unspecific control and murine IgG as
unspecific control for E-cadherin antibody.
Immunocytochemistry
Cells were fixed with methanol (20 1C) for 10minutes. After
washing in PBS and blocking with 3% BSA in PBS for 15minutes, the
cells were incubated with primary antibodies diluted in PBS
containing 1% BSA (ADAM10, 10 mgml1; C36, 1 mgml1) for
1 hour at room temperature. The cells were washed three times with
PBS containing 0.2% BSA and then incubated with anti-mouse Alexa
Fluor 594 and anti-rabbit Alexa Fluor 488 (all Molecular Probes,
Carlsbad, CA; 1:300). The coverslips were mounted in Mowiol
supplemented with 40,6-diamidino-2-phenylindole.
RNA preparation and TaqMan real-time PCR
Total RNA was extracted from three independent cultures using 1ml
TRIzol (Invitrogen) followed by chloroform (Promochem, Wesel,
Germany) and isopropanol (Roth) precipitation as described by the
manufacturer. RNA quantity and quality were determined by
photometry and gel electrophoresis. A 2 mg portion of RNA was
used for DNase I (Qiagen, Hilden, Germany) digestion followed by
reverse transcription with Revert Aid TM H Minus M-MuLV reverse
transcriptase (Fermentas, St Leon-Rot, Germany) using oligo(dt)15
primer (Promega, Mannheim, Germany) according to the manufac-
turer’s instructions. Quantitative real-time PCR was performed in an
ABI PRISM 7000 sequence detection system (Applied Biosystems,
Foster City, CA). Reactions were performed in 20 ml volumes
containing TaqMan Master Mix (Applied Biosystems), Assay-on-
Demand TaqMan primers and probes (Applied Biosystems), and
serial dilutions of cDNA. Following an initial step at 50 1C for
2minutes and denaturation at 95 1C for 10minutes, a PCR was run
with 40 cycles of 15 seconds denaturation at 95 1C, followed by
1minute annealing and amplification at 60 1C. For each sample, a
control without reverse transcriptase was run parallel to allow
assessment of genomic DNA contamination. Each cDNA sample
was analyzed for expression of ADAM10 as well as glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) by quantitative real-time PCR
using the fluorescent TaqMan 50-nuclease assay according to the
manufacturer’s instructions. The mRNA level for the ADAM10 gene
was quantified using the 2DDCT method (Livak and Schmittgen,
2001). For this purpose, CT values for the ADAM10 gene and
GAPDH were determined and DCT values were calculated as CT
ADAM10 geneCT GAPDH. Results were then normalized and
expressed as 2DDCT . The TaqMan assays had the following
identification numbers and reporter sequences, respectively: hA-
DAM 10, Hs00153853_m1, 50-ACAGTGCAGTCCAAGTCAAGGTC
CT-30; hGAPDH, Hs99999905_m1, 50-GGGCGCCTGGTCACCAG
GGCTGCTT-30.
Statistical analysis
All values are expressed as means±SEM. The SE values indicate the
variation between mean values obtained from at least three
independent experiments or as indicated. The assumptions for
normality (Kolmogorov–Smirnov test) and equal variance (Levene’s
median test) were verified with the SigmaStat 3.1 software (SYSSTAT,
Erkrath, Germany). Variance analysis was performed with one- or
two-way analysis of variance. Multiple parametric statistical
comparisons between experimental groups versus a control group
were accomplished with Dunnett’s method. Pair-wise multiple
comparison procedures were performed with Holm–Sidak test.
P-values o0.05 were classified as statistically significant.
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